ProPhase Labs, Inc. Proceeds from Stock Options Exercised
ProPhase Labs, Inc. (PRPH) reported Proceeds from Stock Options Exercised of $337.00 thousand for the 12-month period ending 2018-12-31, per its 10-K filed 2020-03-26.
Discontinued › Cash Flow › Financing Activities
us-gaap:ProceedsFromStockOptionsExercised · last filed 2020-03-26
- ProPhase Labs, Inc. proceeds from stock options exercised for the quarter ending 2018-12-31 was -$1.00K, a 100.15% decline year-over-year.
- ProPhase Labs, Inc. proceeds from stock options exercised for the quarter ending 2018-09-30 was $0.00, a 100.00% decline year-over-year.
- ProPhase Labs, Inc. proceeds from stock options exercised for the quarter ending 2017-12-31 was $656.00K.
- ProPhase Labs, Inc. proceeds from stock options exercised for the quarter ending 2017-09-30 was $752.00K.
- ProPhase Labs, Inc. proceeds from stock options exercised for fiscal 2018 was $337.00K, a 77.68% decline from fiscal 2017.
- ProPhase Labs, Inc. proceeds from stock options exercised for fiscal 2017 was $1.51M.
- ProPhase Labs, Inc. proceeds from stock options exercised for fiscal 2014 was $0.00, a 100.00% decline from fiscal 2013.
- ProPhase Labs, Inc. proceeds from stock options exercised for fiscal 2013 was $27.00K.
| Period end | Proceeds from Stock Options Exercised 3 month | Proceeds from Stock Options Exercised 6 month | Proceeds from Stock Options Exercised 9 month | Proceeds from Stock Options Exercised 12 month |
|---|---|---|---|---|
| 2018-12-31 | -$1.00K derived: 10-K 12 month − 10-Q 9 month · filed 2020-03-26 | -$1.00K derived: sum of 2 quarters · filed 2020-03-26 | $337.00K 10-K · filed 2020-03-26 | |
| 2018-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-12 | $338.00K 10-Q · filed 2019-11-12 | ||
| 2018-06-30 | $338.00K 10-Q · filed 2019-08-12 | |||
| 2017-12-31 | $656.00K derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-26 | $1.41M derived: sum of 2 quarters · filed 2019-03-26 | $1.51M 10-K · filed 2019-03-26 | |
| 2017-09-30 | $752.00K derived: 10-Q 9 month − 10-Q/A 6 month · filed 2018-11-14 | $854.00K 10-Q · filed 2018-11-14 | ||
| 2017-06-30 | $102.00K 10-Q/A · filed 2018-08-20 | |||
| 2014-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $0.00 10-K · filed 2015-03-27 | ||
| 2014-09-30 | $0.00 10-Q · filed 2014-11-13 | |||
| 2013-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2016-03-29 | $27.00K 10-K · filed 2016-03-29 | ||
| 2013-09-30 | $27.00K 10-Q · filed 2014-11-13 | |||
| 2012-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2015-03-27 | $0.00 10-K · filed 2015-03-27 | ||
| 2012-09-30 | $0.00 10-Q · filed 2013-11-13 | |||
| 2011-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2014-03-27 | $0.00 derived: sum of 2 quarters · filed 2014-03-27 | $0.00 10-K · filed 2014-03-27 | |
| 2011-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | $0.00 10-Q · filed 2011-11-14 | ||
| 2011-06-30 | $0.00 10-Q · filed 2011-08-12 | |||
| 2010-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-28 | $0.00 derived: sum of 2 quarters · filed 2013-03-28 | $133.00K 10-K · filed 2013-03-28 | |
| 2010-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2011-11-14 | $133.00K 10-Q · filed 2011-11-14 | ||
| 2010-06-30 | $133.00K 10-Q · filed 2011-08-12 | |||
| 2009-12-31 | $127.00K 10-K · filed 2012-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Xenetic Biosciences, Inc. (XBIO) | United States | $0.006B | |
| Processa Pharmaceuticals, Inc. (PCSA) | United States | $0.005B | |
| Pulmatrix, Inc. (PULM) | United States | $0.006B | |
| AMARIN CORP PLC\UK (AMRN) | $0.005B | -247.24 | |
| Ernexa Therapeutics Inc. (ERNA) | United States | $0.006B | |
| Dermata Therapeutics, Inc. (DRMA) | United States | $0.005B | -0.62 |
| REVIVA PHARMACEUTICALS HOLDINGS, INC. (RVPH) | United States | $0.005B | |
| Enveric Biosciences, Inc. (ENVB) | United States | $0.007B | -0.63 |
| Cadrenal Therapeutics, Inc. (CVKD) | United States | $0.004B | -0.90 |
| Bolt Biotherapeutics, Inc. (BOLT) | United States | $0.007B | -0.26 |